<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>108(5)</volume><submitter>Bun SS</submitter><pubmed_abstract>Association between Hydroxychloroquine (HCQ) and Azithromycin (AZT) is under evaluation for patients with lower respiratory tract infection (LRTI) caused by the Severe Acute Respiratory Syndrome (SARS-CoV-2). Both drugs have a known torsadogenic potential, but sparse data are available concerning QT prolongation induced by this association. Our objective was to assess for COVID-19 LRTI variations of QT interval under HCQ/AZT in patients hospitalized, and to compare manual versus automated QT measurements. Before therapy initiation, a baseline 12 lead-ECG was electronically sent to our cardiology department for automated and manual QT analysis (Bazett and Fridericia's correction), repeated 2 days after initiation. According to our institutional protocol (Pasteur University Hospital), HCQ/AZ</pubmed_abstract><journal>Clinical pharmacology and therapeutics</journal><pagination>1090-1097</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC7361407</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>QT Interval Prolongation Under Hydroxychloroquine/Azithromycin Association for Inpatients With SARS-CoV-2 Lower Respiratory Tract Infection.</pubmed_title><pmcid>PMC7361407</pmcid><pubmed_authors>Marquette CH</pubmed_authors><pubmed_authors>Esnault V</pubmed_authors><pubmed_authors>Theodore G</pubmed_authors><pubmed_authors>Bun SS</pubmed_authors><pubmed_authors>Levraut J</pubmed_authors><pubmed_authors>Squara F</pubmed_authors><pubmed_authors>Dellamonica J</pubmed_authors><pubmed_authors>Baudouy D</pubmed_authors><pubmed_authors>Labbaoui M</pubmed_authors><pubmed_authors>Taghji P</pubmed_authors><pubmed_authors>Doyen D</pubmed_authors><pubmed_authors>Ferrari E</pubmed_authors><pubmed_authors>Scarlatti D</pubmed_authors><pubmed_authors>Sartre B</pubmed_authors><pubmed_authors>Courjon J</pubmed_authors></additional><is_claimable>false</is_claimable><name>QT Interval Prolongation Under Hydroxychloroquine/Azithromycin Association for Inpatients With SARS-CoV-2 Lower Respiratory Tract Infection.</name><description>Association between Hydroxychloroquine (HCQ) and Azithromycin (AZT) is under evaluation for patients with lower respiratory tract infection (LRTI) caused by the Severe Acute Respiratory Syndrome (SARS-CoV-2). Both drugs have a known torsadogenic potential, but sparse data are available concerning QT prolongation induced by this association. Our objective was to assess for COVID-19 LRTI variations of QT interval under HCQ/AZT in patients hospitalized, and to compare manual versus automated QT measurements. Before therapy initiation, a baseline 12 lead-ECG was electronically sent to our cardiology department for automated and manual QT analysis (Bazett and Fridericia's correction), repeated 2 days after initiation. According to our institutional protocol (Pasteur University Hospital), HCQ/AZ</description><dates><release>2020-01-01T00:00:00Z</release><publication>2020 Nov</publication><modification>2025-04-04T09:41:17.192Z</modification><creation>2025-04-04T09:41:17.192Z</creation></dates><accession>S-EPMC7361407</accession><cross_references><pubmed>32588427</pubmed><doi>10.1002/cpt.1968</doi></cross_references></HashMap>